Spiro-isoquinoline-3,4′-piperidine compounds having activity against pain

1. A compound of formula (I):

wherein

m is 0, 1, 2, 3, 4, 5 or 6;

n is 0, 1, 2, 3 or 4;

p is 1, 2, 3 or 4;

R 1 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, —C(O)R 6 , —C(O)OR 6 , —C(O)NR 6 R 6′ and —S(O) 2 R 6 ;

wherein R 6 and R 6′ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted alkylcycloalkyl, and substituted or unsubstituted heterocyclyl or substituted or unsubstituted alkyheterocylcyl;

R 2 is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

wherein said cycloalkyl, aryl or heterocyclyl in R 2 , if substituted, is substituted with one or more substituent/s selected from halogen, —R 12 , —OR 12 , —NO 2 , —NR 12 R 12′″ , NR 12 C(O)R 12′ , —S(O) 2 NR 12 R 12′ , —NR 12 C(O)NR 12′ R 12″ , —SR 12 , —S(O)R 12 , S(O) 2 R 12 , —CN, haloalkyl, haloalkoxy, —C(O)OR 12 , —C(O)NR 12 R 12′ , and —NR 12 S(O) 2 NR 12′ R 12″ ;

wherein, said cycloalkyl or non-aromatic heterocyclyl in R 2 , if substituted, may also be substituted with

 or ═O;

wherein R 12 , R 12′ and R 12″ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, and unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl;

and wherein R 12′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

X is selected from a bond, —C(R x R x′ )— and —C(R x )(OR 7 )—;

R x is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, —C(O)OR 7 , —C(O)NR 7 R 7′ , —NR 7 C(O)R 7′ , and —NR 7 R 7′″ ;

R x′ is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;

R 7 and R 7′ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

and wherein R 7′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 3 is selected from hydrogen, halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NC(O)OR 9 , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , —NR 9 S(O) 2 NR 9′ R 9″ and —OC(O)R 9 ;

R 3′ , R 3″ and R 3′″ are independently selected from hydrogen, halogen, —R 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NC(O)OR 9 , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , —NR 9 S(O) 2 NR 9′ R 9″ and —OC(O)R 9 ;

wherein R 9 , R 9′ and R 9″ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

and wherein R 9′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 4 is selected from hydrogen, —OR 8 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, —C(O)OR 8 , —C(O)NR 8 R 8′ , —NR 8 C(O)R 8′ , —NR 8 R 8′″ and —NC(O)OR 8 ;

R 4′ is selected from hydrogen, or substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;

wherein R 8 and R 8′ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

and wherein R 8′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

alternatively, R 4 and R 4′ may form together with the carbon to which they are attached, a C═O group;

R 5 and R 5′ are independently selected from hydrogen, or substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;

or a stereoisomer, an enantiomer or a diastereomer thereof, or a racemate thereof, or a mixture in any mixing ratio of two stereoisomers, enantiomers and/or diastereomers thereof, or a salt or a solvate thereof;

wherein the following compound is excluded:

or a salt thereof.

2. The compound according to claim 1 , wherein

m is 0 or 1, n is 0 or 1 and p is 1.

3. The compound according to claim 1 , wherein

R 1 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, and —C(O)R 6 ;

and wherein R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl.

4. The compound according to claim 1 , wherein

R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl.

5. The compound according to claim 1 , wherein

X is selected from a bond and —(CR x R x′ )—; and wherein

R x is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;

R x′ is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl.

6. The compound according to claim 1 , wherein

R 3 is selected from hydrogen, halogen, —R 9 , —OR 9 , and —NR 9 R 9′″ ; and

R 3′ , R 3″ and R 3′″ are independently selected from hydrogen, halogen, —R 9 , and —NR 9 R 9′″ ;

wherein R 9 , R 9′ and R 9″ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl; and

R 9′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc.

7. The compound according to claim 1 , wherein

R 4 is selected from hydrogen, —OR 8 , substituted or unsubstituted C 1-6 alkyl;

R 4′ is selected from hydrogen, or substituted or unsubstituted C 1-6 alkyl;

and wherein R 8 is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

or

R 4 and R 4′ form together with the carbon to which they are attached, a C═O group.

8. The compound according to claim 1 , wherein X is a bond.

9. The compound according to claim 1 , wherein

m is 0 or 1;

n is 0 or 1;

p is 1;

R 1 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, and —C(O)R 6 ;

R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

X is a bond;

R 3 , R 3′ , R 3″ and R 3′″ are all hydrogen;

R 4 and R 4′ are both hydrogen, or may form together with the carbon to which they are attached, a C═O group;

R 5 and R 5′ are both hydrogen;

and

R 6 is substituted or unsubstituted C 1-6 alkyl.

10. The compound according to claim 9 , wherein R 1 is substituted or unsubstituted methyl.

11. The compound according to claim 9 , wherein R 2 is substituted or unsubstituted phenyl or substituted or unsubstituted morpholine.

12. The compound according to claim 9 , wherein R 6 is substituted or unsubstituted methyl.

13. The compound according to claim 1 , wherein the compound is selected from:

1′-phenethyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidin]-1-one,

1′-benzyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidin]-1-one,

1′-phenethyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidine],

1′-benzyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidine],

1-(1′-phenethyl-1H-spiro[isoquinoline-3,4′-piperidine]-2(4H)-yl)ethanone,

1′-benzyl-2-methyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidine] and

4-(2-(2-methyl-2,4-dihydro-1H-spiro[isoquinoline-3,4′-piperidine]-1′-yl)ethyl)morpholine.

14. A process for the preparation of the compound of Formula (I) according to claim 1 , which comprises reacting a compound of Formula (Ib′)

with a compound of Formula (XIa) in an alkylating reaction, (XIb) in a reductive amination reaction, (XIc) in an acylation reaction or (XId) in an acylation reaction

wherein m, n, p, R 1 , R 2 , R 3 , R 3′ , R 3″ , R 3′″ , R 4 , R 4′ , R 5 , R 5′ , R 6 and X have the meaning as defined in claim 1 for the compound of Formula (I), L is a leaving group and W is chloro, bromo, —OH, —O-methyl or —O-ethyl.

15. A process for the preparation of the compound of Formula (I) according to claim 1 , employing a compound of Formula IIa, IIb, III, IVa, IVb, Va, Vb, VIa, VIb, VIIa, VIIb, VIII, Ia, IX, Ib, X, Ic, XIa, XIb, XIc, XId, XII, XIIIa, XIIIb, XIV, XV, XVI, XVII, XVII′, Ib′, X′, Ic′, IX′ or Ib′:

wherein m, n, p, R 1 , R 2 , R 3 , R 3′ , R 3″ , R 3′″ , R 4 , R 4′ , R 5 , R 5′ , R 6 and X have the meaning as defined in claim 1 for the compound of Formula (I), L is a leaving group, W is chloro, bromo, —OH, —O-methyl or —O-ethyl, PG is a protecting group and Y is

16. A pharmaceutical composition which comprises the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

17. A method of treating a sigma-1 (σ 1 ) receptor related disease in a subject in need thereof, comprising administration of an effective amount of the compound according to claim 1 .

18. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of the compound according to claim 1 .

19. The method according to claim 18 , wherein the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia, or hyperalgesia.